Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

NCT03476135 | Completed Phase 3 Results FDA Drug

• 3 other identifiers: MET622017-001993-40U1111-1183-5988
• Study Type: interventional
• Target: 91
• Locations: 1 country
• Sites: 8

Brief Summary

This was an open-label, multi-center study to describe the immune persistence of the priming dose and describe the immunogenicity and safety of a booster dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) conjugate vaccine in children in Finland who had been vaccinated 3 years earlier as toddlers with either MenACYW conjugate vaccine or Nimenrix® as part of the MET54 study (NCT03205358). The objectives were:

• To describe the antibody persistence of meningococcal serogroups A, C, Y, and W before a booster dose in children who received either MenACYW conjugate vaccine or Nimenrix® 3 years earlier as toddlers.
• To describe the antibody responses to meningococcal serogroups A, C, Y, and W 30 days after a booster dose of MenACYW conjugate vaccine in children who received either MenACYW conjugate vaccine or Nimenrix® 3 years earlier as toddlers.
• To describe the antibody responses against tetanus toxoid 30 days after a booster dose of MenACYW conjugate vaccine in children who received either MenACYW conjugate vaccine or Nimenrix® 3 years earlier as toddlers.
• To describe the safety profile of a booster dose of MenACYW conjugate vaccine in children who received either MenACYW conjugate vaccine or Nimenrix® 3 years earlier as toddlers.

Conditions

Meningococcal Infections

Keywords

Meningococcal Meningitis; MenACYW conjugate vaccine; Quadrivalent meningococcal vaccine

Outcome Measures

Primary Outcomes (12)

• Antibody Titers Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Before a Booster Dose of MenACYW Conjugate Vaccine in MET62

  Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.

  Day 0 (pre-vaccination)

• Antibody Titers Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After a Booster Dose of MenACYW Conjugate Vaccine in MET62

  Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.

  Day 30 (post-booster vaccination)

• Antibody Titers Measured by Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Against Meningococcal Serogroups A, C, Y, and W Before a Booster Dose of MenACYW Conjugate Vaccine in MET62

  Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.

  Day 0 (pre-vaccination)

• Antibody Titers Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After a Booster Dose of MenACYW Conjugate Vaccine in MET62

  Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.

  Day 30 (post-booster vaccination)

• Antibody Titers Measured by hSBA Against Meningococcal Serogroups A, C, Y, and W After Priming Vaccination in MET54 and Booster Vaccination in MET62

  Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA.

  Day 0 (pre-vaccination) and Day 30 (post-priming vaccination) in study MET54, and Day 0 (pre-vaccination) and Day 30 (post-booster vaccination) in study MET62

• Antibody Titers Measured by rSBA Against Meningococcal Serogroups A, C, Y, and W After Priming Vaccination in MET54 and Booster Vaccination in MET62

  Antibody titers against meningococcal serogroups A, C, Y, and W were measured by rSBA.

  Day 0 (pre-vaccination) and Day 30 (post-priming vaccination) in study MET54, and Day 0 (pre-vaccination) and Day 30 (post-booster vaccination) in study MET62

• Antibody Concentrations Against Tetanus Toxoid Before a Booster Dose of MenACYW Conjugate Vaccine in MET62

  Anti-tetanus antibodies were measured by electrochemiluminescent (ECL) assay.

  Day 0 (pre-vaccination)

• Antibody Concentrations Against Tetanus Toxoid After a Booster Dose of MenACYW Conjugate Vaccine in MET62

  Anti-tetanus antibodies were measured by ECL assay.

  Day 30 (post-booster vaccination)

• Number of Participants With Immediate Adverse Event After Vaccination in MET62

  Immediate events captured medically relevant unsolicited systemic adverse events (AEs) that occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions.

  Within 30 minutes after vaccination

• Number of Participants With Solicited Injection Site Reactions and Systemic Reactions in MET62

  A solicited reaction (SR) was an adverse reaction (AR) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. Solicited injection site reactions: pain, erythema, and swelling. Solicited systemic reactions: fever, headache, malaise and, myalgia.

  Within 7 days after vaccination

• Number of Participants With Unsolicited Adverse Event After Vaccination in MET62

  An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination.

  Within 30 days after vaccination

• Number of Participants With a Serious Adverse Event (SAE) After Vaccination in MET62

  A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event.

  Within 30 days after vaccination

Study Arms (2)

Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)

EXPERIMENTAL

Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).

Biological: MenACYW conjugate vaccine

Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)

EXPERIMENTAL

Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).

Biological: MenACYW conjugate vaccine

Interventions

MenACYW conjugate vaccine BIOLOGICAL

Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular

Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW); Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)

Eligibility Criteria

• Age: 46 Months - 61 Months
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Participated in and completed (attended Visit 2) study MET54.
• Informed consent form had been signed and dated by the parent(s) or another legally acceptable representative (and by an independent witness, if required by local regulations).
• Participant and parent/legally acceptable representative were able to attend all scheduled visits and complied with all trial procedures.
• Covered by health insurance where applicable.

You may not qualify if:

• Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
• Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which might be received at a gap of at least 2 weeks before or after the study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines. If the participant was due to receive vaccination(s) recommended for his/her age by the national immunization schedule at the time of the study, the participant was recommended to complete his/her immunization schedule after Visit 2.
• Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B vaccine) with the exception of the single dose of meningococcal vaccine administered as part of study MET54.
• Receipt of immune globulins, blood or blood-derived products in the past 3 months.
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
• History of meningococcal infection, confirmed either clinically, serologically, or microbiologically
• At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease).
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
• Verbal report of thrombocytopenia, contraindicating intramuscular vaccination in the Investigator's opinion.
• Personal history of Guillain-Barré syndrome.
• Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine.
• Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion.
• Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature \>= 38.0 degree Celsius \[°C\]). A prospective participant was not included in the study until the condition had resolved or the febrile event had subsided.
• Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
• Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.

Sponsors & Collaborators

• Sanofi Pasteur, a Sanofi Company: lead

Study Sites (8)

Sanofi Pasteur Investigational Site 2460005

Espoo, 02230, Finland

Location

Sanofi Pasteur Investigational Site 2460006

Helsinki, 00100, Finland

Location

Sanofi Pasteur Investigational Site 2460002

Helsinki, 00930, Finland

Location

Sanofi Pasteur Investigational Site 2460007

Jarvenpaa, 04400, Finland

Location

Sanofi Pasteur Investigational Site 2460008

Oulu, 90220, Finland

Location

Sanofi Pasteur Investigational Site 2460001

Pori, 28100, Finland

Location

Sanofi Pasteur Investigational Site 2460003

Tampere, 33100, Finland

Location

Sanofi Pasteur Investigational Site 2460004

Turku, 20520, Finland

Location

MeSH Terms

Conditions

Meningococcal Infections; Meningitis, Meningococcal

Condition Hierarchy (Ancestors)

Neisseriaceae Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Meningitis, Bacterial; Central Nervous System Bacterial Infections; Central Nervous System Infections; Central Nervous System Diseases; Nervous System Diseases; Meningitis; Neuroinflammatory Diseases

Results Point of Contact

• Title: Trial Transparency Team
• Organization: Sanofi Pasteur

Contact-US@sanofi.com

800-633-1610

Study Officials

• Medical Director

  Sanofi Pasteur, a Sanofi Company

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 19, 2018
• First Posted: March 23, 2018
• Study Start: February 27, 2018
• Primary Completion: September 10, 2018
• Study Completion: September 10, 2018
• Last Updated: April 6, 2022
• Results First Posted: June 5, 2020

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will share

Locations

FI (8)